Loading clinical trials...

Diagnostic Validity of [18F]FSPG PET for the Assessment of Disease Activity in Inflammatory Bowel Disease | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Diagnostic Validity of [18F]FSPG PET for the Assessment of Disease Activity in Inflammatory Bowel Disease

Phase 2, Open-label, Non-randomized, Single Center Study to Explore Diagnostic Validity of [18F]FSPG PET for the Assessment of Disease Activity in Subjects With Inflammatory Bowel Disease.

NCT03546868•Asan Foundation

View on ClinicalTrials.gov

Summary

Diagnostic validity of \[18F\]FSPG for assessing disease activity will be assessed in subjects with inflammatory bowel disease.

Detailed Description

\[18F\]FSPG PET/CT imaging will noninvasively assess system xc- of cancer and inflammation. Diagnostic validity of \[18F\]FSPG for assessing disease activity will be assessed in subjects with inflammatory bowel disease.

Eligibility

Age

19 - 79 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Subject is aged between 19 and 79 years and male or female of any race/ethnicity.
•Subject has had ulcerative colitis or Crohn's disease diagnosed by clinical, endoscopic and histologic evidence at least 3 months prior to screening.
•Subject has symptoms suggestive of active disease at the time of enrollment.
•Subject is scheduled to undergo sigmoidoscopy or colonoscopy for ulcerative colitis or Crohn's disease within 7 days prior to or after the planned study with \[18F\]FSPG administration.

Exclusion Criteria

•Subject or subject's legally acceptable representative does not provide written informed consent.
•Subject displays clinical signs of ischemic colitis or has an evidence of pathogenic bowel infection.
•Subject is diagnosed as having inflammatory bowel disease unclassified.
•Subject has been treated with sulfasalazine or intravenous corticosteroids within the previous four weeks prior to the planned study with \[18F\]FSPG administration.
•Dose escalation of the current inflammatory bowel disease drugs or starting a new oral aminosalicylate, corticosteroid, immunomodulator, biologics, antibiotics, probiotics, or topical preparations is scheduled from the study enrollment to the scheduled sigmoidoscopy or colonoscopy, or 24 hours after \[18F\]FSPG administration . The dose escalation or starting a new antidiarrheal and/or analgesic drug is allowed.
•Female subject is pregnant or nursing. Exclusion of the possibility of pregnancy is made by one of the following: 1) Woman is physiologically post-menopausal (cessation of menses for more than 2 years), 2) woman is surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy, or 3) if the woman is of childbearing potential, a serum or urine pregnancy test performed within 24 hours immediately prior to administration of \[18F\]FSPG has to be negative and the women is advised to apply contraceptive measures during her participation in this study.
•Subject has concurrent severe and/or uncontrolled and/or unstable medical disease (e.g. congestive heart failure, acute myocardial infarction, severe pulmonary disease, chronic renal or hepatic disease which could compromise participation in the study) in the judgment of the investigator.
•Subject is a relative of the investigator, student of the investigator or otherwise dependent.
•Subject has received any investigational drugs or devices within four weeks prior to the study enrollment.
•Subject has been previously included in this study.
+2 more criteria

Locations (2)

Asan Foundation

Seoul, Songpa-gu, South Korea

Asan Foundation

Seoul, South Korea

Key Dates

Start Date

August 14, 2018

Primary Completion Date

January 11, 2019

Completion Date

January 11, 2019

Last Updated

December 14, 2020

Enrollment

ACTUAL participants

Conditions

Inflammatory Bowel DiseasesUlcerative ColitisCrohn Disease

Interventions

[18F]FSPG

DRUG

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

NCT06226883

Inflammatory Bowel DiseasesCrohn's Disease

View study

RECRUITING

Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis

NCT07271069

Ulcerative Colitis (UC)

View study

RECRUITINGPHASE2

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 14, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Diagnostic Validity of [18F]FSPG PET for the Assessment of Disease Activity in Inflammatory Bowel Disease

Inclusion Criteria

Exclusion Criteria

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis

A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)